Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

NCT05789069 is registered in ClinicalTrials.gov with HiFiBiO Therapeutics as lead sponsor.

NCT NCT05789069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Lead sponsor
HiFiBiO Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 9, 2023
Completion date
December 31, 2026
Enrollment
83 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, melanoma, non small cell lung cancer, renal cell carcinoma